Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F | O60840 | 5/20 | 0.48 |
| ▸ | CACNA1D | Q01668 | 5/20 | 0.48 |
| ▸ | CACNA1S | Q13698 | 5/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 5/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 9/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 9/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 9/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6713558 | 0.91 | CACNA1F (0.47) | CACNA1FCACNA1DCACNA1SCACNA1CADRA1D | |
| SCHEMBL6193641 | 0.91 | ADRA1D (0.54) | CACNA1FCACNA1DCACNA1SCACNA1CADRA1D | |
| SCHEMBL7162576 | 0.91 | ADRA1D (0.54) | CACNA1FCACNA1DCACNA1SCACNA1CADRA1D | |
| SCHEMBL6898111 | 0.89 | CACNA1F (0.48) | CACNA1FCACNA1DCACNA1SCACNA1CADRA1D | |
| SCHEMBL6715316 | 0.85 | CACNA1F (0.44) | CACNA1FCACNA1DCACNA1SCACNA1CADRA1D | |
| SCHEMBL6713491 | 0.84 | CACNA1F (0.44) | CACNA1FCACNA1DCACNA1SCACNA1CADRA1D | |
| SCHEMBL6772145 | 0.81 | CACNA1F (0.39) | CACNA1FCACNA1DCACNA1SCACNA1CADRA1D | |
| SCHEMBL6772155 | 0.81 | CACNA1F (0.39) | CACNA1FCACNA1DCACNA1SCACNA1CADRA1D | |
| SCHEMBL6198625 | 0.81 | ADRA1D (0.45) | CACNA1FCACNA1DCACNA1SCACNA1CADRA1D | |
| SCHEMBL6196834 | 0.81 | ADRA1D (0.51) | ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727257-B1 | HYPOTENSIVE AGENTS FOR INTRAOCULAR PRESSURE; ANTICHOLESTEROL AGENTS; RELAXING URINARY TRACT TISSUE; BENIGN PROSTATIC HYPERPLASIA, IMPOTENCY, AND CARDIOVASCULAR DISORDERS; ANTIARRHYTHMIA AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-20040038855-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2004-02-26 | — | — | US | disclosed |
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-01-24 | — | — | US | disclosed |
| US-6245773-B1 | BENIGN PROSTATIC HYPERPLAMIA; REDUCTION OF INTRAOCULAR PRESSURE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-06-12 | — | — | US | disclosed |
| WO-1996014846-A1 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | QDPR, DPYD, ADRA1D | CACNA1F 588/4885CACNA1D 265/4885CACNA1S 422/4885 |
| US-20040038855-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | CACNA1F 3536/4885CACNA1D 3176/4885CACNA1S 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.